This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignees: National University Corporation Tokai National Higher Education and Research System, Yamasa Corporation. Active years: 2023.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:

Years Active: 2023
Title: Ryohei Kajino: Innovator in Nucleoside Derivatives
Introduction
Ryohei Kajino is a notable inventor based in Gifu, Japan. He has made significant contributions to the field of pharmaceuticals, particularly in the development of nucleoside derivatives. His work focuses on creating more practical solutions for RNA pharmaceuticals and other applications.
Latest Patents
Ryohei Kajino holds a patent for a nucleoside derivative, which is represented by specific chemical formulas. This invention aims to enhance the practicality of nucleosides for various pharmaceutical applications. The patent details a nucleoside that can be represented by formula (1) or (2), or a salt thereof. In formula (1), R represents a hydrogen atom, a hydroxyl group, or a protected group, while in formula (2), X represents a halogen atom. The versatility of these compounds makes them valuable in the pharmaceutical industry.
Career Highlights
Throughout his career, Ryohei Kajino has worked with reputable organizations, including Yamasa Corporation and the National University Corporation Tokai National Higher Education and Research System. His experience in these institutions has allowed him to develop his expertise in the field of nucleoside chemistry.
Collaborations
Ryohei has collaborated with notable colleagues such as Yoshihito Ueno and Yusuke Maeda. These partnerships have contributed to the advancement of his research and the successful development of his patented inventions.
Conclusion
Ryohei Kajino's innovative work in nucleoside derivatives showcases his commitment to advancing pharmaceutical applications. His contributions are significant in the realm of RNA pharmaceuticals, and his collaborations further enhance the impact of his inventions.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile